SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aeglea BioTherapeutics, Inc. (AGLE) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AGLE
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.98
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-24.71 |
$6.09M |
$-11.3M |
-185.6% |
| 2016 |
$-55.40 |
$4.63M |
$-21.7M |
-468.8% |
| 2017 |
$-45.01 |
$5.21M |
$-27.24M |
-523.3% |
| 2018 |
$-53.25 |
$3.89M |
$-44.35M |
-1140.6% |
| 2019 |
$-59.23 |
$0.00 |
$-75.69M |
- |
| 2020 |
$-37.61 |
$0.00 |
$-80.3M |
- |
| 2021 |
$-25.02 |
$18.74M |
$-65.8M |
-351.1% |
| 2022 |
$-24.86 |
$2.33M |
$-83.82M |
-3598.8% |
| 2024 |
$-0.56 |
$0.00 |
$-208.02M |
- |
| 2025 |
$-1.98 |
$0.00 |
$-155.2M |
- |
